Literature DB >> 30375531

An Atypical Syndrome in an Elderly Patient With Systemic Lupus Erythematosus, Sjögren Syndrome, and Primary Biliary Cirrhosis.

Xiaojuan Song1, Xia Rong1, Yi Liu1.   

Abstract

Posterior reversible encephalopathy syndrome is a clinico-radiological syndrome with numerous entities including hypertension, preeclampsia/ eclampsia, renal dysfunction, cytotoxic drugs, systemic infections, and autoimmune diseases. It is a rare happening in patients with autoimmune disease. In this article, we report a case of an elderly female patient having the syndrome, meanwhile, also diagnosed with systemic lupus erythematosus, Sjögren syndrome, and primary biliary cirrhosis.

Entities:  

Keywords:  Primary biliary cirrhosis; Sjögren syndrome; posterior reversible encephalopathy syndrome; systemic lupus erythematous

Year:  2017        PMID: 30375531      PMCID: PMC6190953          DOI: 10.5606/ArchRheumatol.2017.6124

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  10 in total

1.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 2.  Developments in autoimmune channelopathies.

Authors:  Angela Vincent
Journal:  Autoimmun Rev       Date:  2012-11-30       Impact factor: 9.754

3.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 4.  [Posterior reversible encephalopathy syndrome].

Authors:  M Fischer; E Schmutzhard
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-06       Impact factor: 0.840

5.  Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Seth G Thacker; Celine C Berthier; Clemens D Cohen; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2011-11-04       Impact factor: 5.422

6.  Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study.

Authors:  Javier Merayo-Chalico; Elia Apodaca; Ana Barrera-Vargas; Jorge Alcocer-Varela; Iris Colunga-Pedraza; Alejandra González-Patiño; Antonio Arauz; Carlos Abud-Mendoza; Marco Martínez-Martínez; Diana Gómez-Martín
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-03-24       Impact factor: 10.154

7.  Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2.

Authors:  Carmelo Carmona-Rivera; Wenpu Zhao; Srilakshmi Yalavarthi; Mariana J Kaplan
Journal:  Ann Rheum Dis       Date:  2014-02-25       Impact factor: 19.103

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  Late-onset systemic lupus erythematosus-associated primary biliary cirrhosis.

Authors:  Sonia Hammami; Nabil Chaabane; Houda Mahmoudi; Fethia Bdioui; Hamouda Saffar
Journal:  Int Arch Med       Date:  2013-02-05

Review 10.  Role of osteopontin in systemic lupus erythematosus.

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-06-11       Impact factor: 4.291

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.